BridgeBio Pharma (BBIO) EBIT Margin (2019 - 2026)
BridgeBio Pharma (BBIO) posted EBIT Margin of 54.47% for Q1 2026, up 39.82% sequentially from 90.52% in Q4 2025, and up 3502.0% YoY from 1.51% in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) EBIT Margin (2019 - 2026) Analysis & Trends
BridgeBio Pharma has reported EBIT Margin for 8 years, with the latest figure at 54.47% in Q1 2026.
- Quarterly EBIT Margin rose 3502.0% year-over-year to 54.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.52% (up 45705.0% YoY) and the FY2025 annual result came in at 104.25%, up 16297.0% from the prior year.
- EBIT Margin rose to 54.47% in Q1 2026 per BBIO's latest filing, from 90.52% in the prior quarter.
- Over five years, EBIT Margin peaked at 0.16% in Q1 2024 and troughed at 38200.0% in Q3 2022.
- A 5-year average of 6161.19% and a median of 3854.61% in 2023 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin slumped 3182206 bps in 2022, then soared 3434539 bps in 2023.
- Over 5 years, EBIT Margin stood at 6910.8% in 2022, then slumped by 47 bps to 10167.11% in 2023, then jumped by 62 bps to 3842.69% in 2024, then surged by 98 bps to 90.52% in 2025, then surged by 40 bps to 54.47% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 54.47%, 90.52%, and 120.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -43.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.94% |
| Mar 31, 2026 | -54.47% |
| Dec 31, 2025 | -90.52% |
| Sep 30, 2025 | -120.30% |
| Jun 30, 2025 | -121.45% |
| Mar 31, 2025 | -89.49% |
| Dec 31, 2024 | -3,842.69% |
| Sep 30, 2024 | -7,018.67% |
| Jun 30, 2024 | -8,096.82% |
| Mar 31, 2024 | 0.16% |
| Dec 31, 2023 | -10,167.11% |
| Sep 30, 2023 | -3,854.61% |
| Jun 30, 2023 | -8,903.05% |
| Mar 31, 2023 | -6,909.26% |
| Dec 31, 2022 | -6,910.80% |
| Sep 30, 2022 | -38,200.00% |
| Jun 30, 2022 | -108.72% |
| Mar 31, 2022 | -10,252.54% |
| Dec 31, 2021 | -1,656.14% |
| Sep 30, 2021 | -6,377.94% |